{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:40:00Z","timestamp":1764225600003,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.pupt.2020.101946","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T01:35:58Z","timestamp":1600306558000},"page":"101946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-5433","authenticated-orcid":false,"given":"Andreas","family":"Renner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Marth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Patocka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Idzko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2020.101946_bib1","first-page":"9","article-title":"Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?","volume":"10","author":"De Ferrari","year":"2016","journal-title":"Expet Rev. Respir. Med."},{"issue":"6","key":"10.1016\/j.pupt.2020.101946_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01046-2019","article-title":"GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents","volume":"53","author":"Reddel","year":"2019","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101946_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"9842","key":"10.1016\/j.pupt.2020.101946_bib4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.pupt.2020.101946_bib5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.pupt.2020.101946_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.pupt.2020.101946_bib7","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.pupt.2020.101946_bib8","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Therapeut."},{"issue":"5","key":"10.1016\/j.pupt.2020.101946_bib9","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10","key":"10.1016\/j.pupt.2020.101946_bib10","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2020.101946_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1183\/20734735.015414","article-title":"Real-world research and its importance in respiratory medicine","volume":"11","author":"Price","year":"2015","journal-title":"Breathe"},{"issue":"6","key":"10.1016\/j.pupt.2020.101946_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2020.101946_bib13","first-page":"1","article-title":"Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma","author":"Pertzov","year":"2019","journal-title":"J. Asthma"},{"issue":"1","key":"10.1016\/j.pupt.2020.101946_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.pupt.2020.101946_bib15","doi-asserted-by":"crossref","first-page":"101836","DOI":"10.1016\/j.pupt.2019.101836","article-title":"One year of mepolizumab. Efficacy and safety in real-life in Italy","volume":"58","author":"Bagnasco","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"12","key":"10.1016\/j.pupt.2020.101946_bib16","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/all.13937","article-title":"Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation","volume":"74","author":"Bagnasco","year":"2019","journal-title":"Allergy"},{"issue":"12","key":"10.1016\/j.pupt.2020.101946_bib17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17476348.2019.1676734","article-title":"Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response","volume":"13","author":"Caminati","year":"2019","journal-title":"Expet Rev. Respir. Med."},{"key":"10.1016\/j.pupt.2020.101946_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pupt.2018.12.003","article-title":"Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life","volume":"54","author":"Lombardi","year":"2019","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2020.101946_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"author":"Guideline (GINA","key":"10.1016\/j.pupt.2020.101946_bib20"},{"issue":"1","key":"10.1016\/j.pupt.2020.101946_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","article-title":"Development of the asthma control test: a survey for assessing asthma control","volume":"113","author":"Nathan","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.pupt.2020.101946_bib22","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","article-title":"The minimally important difference of the Asthma Control Test","volume":"124","author":"Schatz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.pupt.2020.101946_bib23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.anai.2011.09.001","article-title":"Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria","volume":"107","author":"Korn","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"9972","key":"10.1016\/j.pupt.2020.101946_bib24","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(15)60521-9","article-title":"Smoking ban in Austria: a long overdue step but still a lot to be done","volume":"385","author":"Muttarak","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pupt.2020.101946_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11136-014-0801-x","article-title":"A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales","volume":"24","author":"Hyland","year":"2015","journal-title":"Qual. Life Res."},{"issue":"3","key":"10.1016\/j.pupt.2020.101946_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","article-title":"Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma","volume":"6","author":"Ortega","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.pupt.2020.101946_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/all.14441","article-title":"Benralizumab rapidly improves asthma control in Austrian real-life severe eosinophilic asthmatics","author":"Renner","year":"2020","journal-title":"Allergy"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553920301504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:10Z","timestamp":1761082210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553920301504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"alternative-id":["S1094553920301504"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101946","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2020.101946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101946"}}